Estrogen Added to Cancer List
Although estrogen is used as a treatment for many women, it is also attributed to be a carcinogen. The National Toxicology Program voted that steroidal estrogen should be listed as a cancer-causing substance because of its association with endometrial and breast cancer. Steroidal estrogen is used in post-menopausal treatments and birth control pills.
Doctors have known about the cancer link and usually prescribe post-menopausal estrogen pills along with another hormone called progestin. This combination lowers the risk of endometrial cancer.
The National Institutes of Health updates the federal list of proven and suspected cancer-causing substances every two years.
Information from the AP.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.
CDC Urges Vigilance: New Recommendations for Monitoring and Testing H5N1 Exposures
July 11th 2025With avian influenza A(H5N1) infections surfacing in both animals and humans, the CDC has issued updated guidance calling for aggressive monitoring and targeted testing to contain the virus and protect public health.
IP LifeLine: Layoffs and the Evolving Job Market Landscape for Infection Preventionists
July 11th 2025Infection preventionists, once hailed as indispensable during the pandemic, now face a sobering reality: budget pressures, hiring freezes, and layoffs are reshaping the field, leaving many IPs worried about their future and questioning their value within health care organizations.
